Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The RX CKD source targets 20 mg daily. The separately stored August 2025 label adds an HF target that depends on initiation eGFR and can reach 40 mg.
Before applying: Determine the indication and use its full potassium/eGFR adjustment table. The new HF card is a start/target summary, not every Table 3 restart cell.
Also check: CKD target and newer HF target are not interchangeable
Official source
Finerenone tablets (Kerendia, CKD with type 2 diabetes) - selected U.S. label sections
Product / population
Adult KERENDIA for CKD associated with type 2 diabetes only. The heart-failure indication has a different dosing framework and is not reproduced here.
Renal measure
eGFR in mL/min/1.73 m2 plus serum potassium
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
Renal initiation - CKD with type 2 diabetes
Baseline eGFR
Starting oral dose
60 or higher
20 mg once daily
25 to below 60
10 mg once daily
Below 25
Initiation not recommended
Do not initiate when serum potassium exceeds 5.0 mEq/L.
Follow-up and scope limit
For CKD with type 2 diabetes, the target daily dose is 20 mg. Check potassium 4 weeks after initiation or a dose change; continued dosing also depends on potassium and eGFR. This initial-dose table does not replace the full potassium-based maintenance/withholding table.
Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.
Find text within this drug
Find a term without leaving this drug
Search the stored clinical text
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
indication and label version difference
CKD target and newer HF target are not interchangeable
The RX CKD source targets 20 mg daily. The separately stored August 2025 label adds an HF target that depends on initiation eGFR and can reach 40 mg.
How to use this: Determine the indication and use its full potassium/eGFR adjustment table. The new HF card is a start/target summary, not every Table 3 restart cell.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
Finerenone tablets (Kerendia, CKD with type 2 diabetes) - selected U.S. label sections
Adult KERENDIA for CKD associated with type 2 diabetes only. The heart-failure indication has a different dosing framework and is not reproduced here.
Method: eGFR in mL/min/1.73 m2 plus serum potassium
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
U.S. product labeling / DailyMed · Adult KERENDIA for CKD associated with type 2 diabetes only. The heart-failure indication has a different dosing framework and is not reproduced here.
Renal method: eGFR in mL/min/1.73 m2 plus serum potassium Source date: Revision not captured; retrieval date is not the revision date. Retrieved: 2026-09-05
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Renal initiation - CKD with type 2 diabetes
Baseline eGFR
Starting oral dose
60 or higher
20 mg once daily
25 to below 60
10 mg once daily
Below 25
Initiation not recommended
Do not initiate when serum potassium exceeds 5.0 mEq/L.
For CKD with type 2 diabetes, the target daily dose is 20 mg. Check potassium 4 weeks after initiation or a dose change; continued dosing also depends on potassium and eGFR. This initial-dose table does not replace the full potassium-based maintenance/withholding table.
RDM32-finerenone-kerendia-ckd-2 · Source locator: 2.3, CKD associated with type 2 diabetes
Source-specific limits
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
GlobalRPh-hosted RX List · Retrieved RX version covers CKD associated with type 2 diabetes, not the newer separate HF target.
Renal method: Indexed eGFR mL/min/1.73 m2; potassium also controls dosing. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Start 20 mg daily at eGFR >=60, or 10 mg daily at eGFR 25 to <60; initiation below 25 is not recommended. The target in this CKD source is 20 mg daily. Potassium monitoring and the complete hold/restart table remain necessary; check potassium four weeks after starting and after dose adjustment. This starting-dose excerpt is not the full potassium-based titration algorithm.
RDM41-rxlist-finerenone-kerendia-ckd-df7b112a0c-C1 · Source locator: Dosage / Use in specific populations: renal impairment
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.